Literature DB >> 7538820

Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro.

J Maciejewski1, C Selleri, S Anderson, N S Young.   

Abstract

Activation of Fas antigen, a cell surface receptor molecule, by its ligand results in transduction of a signal for cell death. The Fas system has been implicated in target cell recognition, clonal development of immune effector cells, and termination of the cellular immune response. Fas antigen expression on lymphocytes is regulated by interferon gamma (IFN gamma) and tumor necrosis factor alpha (TNF alpha), cytokines that also have inhibitory effects on hematopoiesis. We investigated Fas antigen expression on human marrow cells and the effects of Fas activation on hematopoiesis in vitro. Freshly isolated immature hematopoietic cells, as defined by the CD34 marker, did not express Fas antigen at levels detectable by fluorescent staining. CD34+ cells, which include progenitors and stem cells, showed low levels of Fas expression in culture, even in the presence of growth factors. Stimulation by TNF alpha and IFN gamma markedly increased Fas antigen expression on CD34+ cells. Anti-Fas antibody, which mimics the action of the putative ligand, enhanced IFN gamma- and TNF alpha-mediated suppression of colony formation by bone marrow (BM) in a dose-dependent manner. This effect did not require the presence of accessory cells. Colony formation from mature (CD34+ CD38+) and immature (CD34+ CD38-) progenitor cells and long-term culture initiating cells were susceptible to the inhibitory action of anti-Fas antibody in the presence of IFN gamma and TNF alpha. Apoptosis assays performed on total BM cells and CD34+ cells showed that anti-Fas antibody induced programmed cell death of CD34+ BM cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538820

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  89 in total

1.  MHC class II upregulation and colocalization with Fas in experimental models of immune-mediated bone marrow failure.

Authors:  Andrew J Erie; Leigh Samsel; Tomoiku Takaku; Marie J Desierto; Keyvan Keyvanfar; J Philip McCoy; Neal S Young; Jichun Chen
Journal:  Exp Hematol       Date:  2011-05-13       Impact factor: 3.084

2.  Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.

Authors:  T Iwasaki; T Hamano; K Saheki; T Kuroiwa; Y Kataoka; Y Takemoto; A Ogata; J Fujimoto; E Kakishita
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 3.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

4.  New challenges to developing animal models for human immune-mediated marrow failure.

Authors:  Antonio M Risitano
Journal:  Clin Med Res       Date:  2005-05

Review 5.  Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases.

Authors:  Yukino Chiba; Izuru Mizoguchi; Hideaki Hasegawa; Mio Ohashi; Naoko Orii; Taro Nagai; Miyaka Sugahara; Yasunori Miyamoto; Mingli Xu; Toshiyuki Owaki; Takayuki Yoshimoto
Journal:  Cell Mol Life Sci       Date:  2017-12-07       Impact factor: 9.261

6.  Negative selection by apoptosis enriches progenitors in naïve and expanded human umbilical cord blood grafts.

Authors:  K Mizrahi; S Ash; T Peled; I Yaniv; J Stein; N Askenasy
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

7.  Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome.

Authors:  Xiao Li; C Eileen Bryant; H Joachim Deeg
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

8.  Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction.

Authors:  Shok Ping Lim; Benedetta Costantini; Syed A Mian; Pilar Perez Abellan; Shreyans Gandhi; Marc Martinez Llordella; Juan Jose Lozano; Rita Antunes Dos Reis; Giovanni A M Povoleri; Thanos P Mourikis; Ander Abarrategi; Linda Ariza-McNaughton; Susanne Heck; Jonathan M Irish; Giovanna Lombardi; Judith C W Marsh; Dominique Bonnet; Shahram Kordasti; Ghulam J Mufti
Journal:  Blood       Date:  2020-08-13       Impact factor: 22.113

Review 9.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

10.  The role of the Th1 transcription factor T-bet in a mouse model of immune-mediated bone-marrow failure.

Authors:  Yong Tang; Marie J Desierto; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.